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Rationale: The acute effect of secondhand smoke (SHS) on lung
function and the duration of system disruption remain unknown.
Objectives: To assess the SHS effects and their duration on lung
function and inflammatory markers.
Methods: In a randomized single-blind crossover experiment data
were obtained from 16 (8 women) nonsmoking adults at baseline
and at 0, 1, and 3 hours after a 1-hour SHS exposure set at bar/
restaurant SHS levels.
Measurements and Main Results: Serum and urine cotinine, lung
function, and cytokines IL-4, IL-5, IL-6, tumor necrosis factor (TNF)-
a, and IFN-g. At 0 hours most lung function parameters were
significantly reduced (indicative: FEV1, 4.3 6 0.4 vs. 3.8 6 0.3 L;
FEV1/FVC, 0.96 0.1 vs. 0.86 0.1; P, 0.05) but at 3 hours they were
at baseline levels. In contrast, cotinine (serum, 8.9 6 3.2 vs. 35.5 6
10.2 ngml21), IL-4 (41.3 6 5.8 vs. 44.2 6 4.5 pgml21), IL-5 (36.1 6
3.2 vs. 60.16 7.0 pgml21), IL-6 (2.56 0.3 vs. 7.66 1.4 pgml21) and
IFN-g (0.36 0.2 vs. 0.66 0.2 IUml21) at 3 hours were higher than at
baseline (P , 0.05). IL-4 and TNF-a increased only in men, whereas
IL-5, IL-6, and IFN-g were different between sexes after exposure
(P, 0.05). Regressionanalyses revealed inverse associations of FEV1
and FEV1/FVC ratio with IL-5 (P , 0.05) in men and with IL-5
(P 5 0.01), IL-6 (P , 0.001), IFN-g (P 5 0.034) and serum cotinine
(P, 0.001) in women.
Conclusions: We conclude that 1 hour of SHS exposure at bar/
restaurant levels is accompanied by significant decrements on lung
function and marked increases in inflammatory cytokines, particu-
larly inmen.More importantly,whereasmost smoke-inducedeffects
on lung function appear to recede within 60 minutes, inflammatory
cytokines remain elevated for at least 3 hours after exposure to SHS.
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In the 10 minutes you will spend reading this article, 111 people
will die somewhere in the world from tobacco-induced illnesses.*
Fourteen of them have never smoked.†
An overwhelming amount of evidence has emerged over the
past decades on the adverse health effects of secondhand smoke
(SHS) (1–5). Nevertheless, more than 126 million American and
130 million Chinese adult nonsmokers suffer daily SHS expo-
sure, whereas global estimates include 700 million children and
50 million pregnant women (1). Latest reports show that,
despite current measures, the prevalence rates of smoking are
increasing (2, 3), while the tobacco industry predicts a global
expansion of the tobacco epidemic in the near future (3).
Moreover, arguments are being expressed that only chronic
exposures to SHS represent a health risk and that there is no
scientific basis for claims that brief, acute, transient SHS
exposures represent a significant acute health hazard in non-
smokers (6). This is, in part, because our knowledge on the
effects of SHS is based predominantly on longitudinal epide-
miological studies, whereas experimental studies assessing the
acute and short-term effects of SHS are scarce. Yet, the latter
are essential and, comparatively, more important in elucidating
the underlying physiological mechanisms involved in SHS-
induced system disruption (7, 8).
Chronic lung disease is generally the result of long-term
processes, yet, even brief SHS exposures appear to initiate
mechanisms that contribute to its development. For instance,
shortly after the beginning of smoke exposure there is a rapid
and marked up-regulation of growth factor production as well
as production of type 1 procollagen in the small airways (9).
Furthermore, spontaneous inhalation of cigarette smoke elicits
acute pulmonary chemoreflexes, characterized by apnea, bra-
dycardia, and hypotension through activation of pulmonary C
fibers (10). These findings are in line with experimental data
from our (11–14) and other (15–17) laboratories showing that
even brief SHS exposures generate unfavorable changes in
various cardiovascular, endocrine, and immune mechanisms.
Additionally, human (12) and animal (18) models suggest an
AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
Epidemiological studies have identified the long-term
detrimental consequences of secondhand smoke (SHS),
but the acute SHS effects and their duration, as well as the
underlying physiological mechanisms, remain unexplored.
What This Study Adds to the Field
A 1-hour moderate SHS exposure is accompanied by sig-
nificantly deteriorated lung function and marked increases
in inflammatory cytokines, particularly in men. Although
most SHS-induced effects on lung function appear to recede
within 60 minutes, inflammatory cytokines remain elevated
for at least 3 hours following SHS exposure.
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association between SHS exposure and elevated proinflamma-
tory cytokines, which may be linked to the development and/or
exacerbation of chronic lung disease. However, the precise
effects of SHS on the respiratory system and cytokine pro-
duction remain elusive. Given the role of inflammation in the
development of impaired respiratory function, understanding
the acute SHS-induced respiratory and immune responses is
crucial (19) because SHS is associated with an increased
prevalence of chronic lung diseases and allergies (20). Notably,
the duration of system disruption after brief SHS exposures has
yet to be elucidated. We conducted a randomized single-blind
crossover experiment to assess lung function and cytokine
responses before as well as 0, 1, and 3 hours after a 1-hour
moderate exposure to SHS.
METHODOLOGY
Participants and Procedures
The experimental protocol was approved by the ethical review
board at the University of Thessaly. Sixteen healthy adults (8
men, 8 women, aged 27.2 6 4.3 yr; body mass index, 22.0 6 1.8)
volunteered. Exclusion criteria included smoking, pregnancy,
evidence of cardiac or pulmonary disease, and previous disease
and medications known to affect lung function. All women
participants were premenopausal with regular menstruation and
were tested during the late luteal phase of their menstrual cycle.
Experimental Design
Participants visited the laboratory at 0730 hours for four trials
conducted in a random order and separated by 7 days. In the
baseline trial (TB) participants were assessed for cotinine, lung
function, and cytokine levels without any SHS exposure pre-
cisely at 1200 hours. In the remaining trials, participants were
exposed to SHS for 1 hour either at 0800 hours (T3), 1000 hours
(T1), or at 1100 hours (T0), while cotinine, lung function, and
cytokine levels were assessed at 1200 hours as illustrated in
Figure 1. See the online supplement for further details.
All testing was conducted by the same trained investigators,
who were unaware of the specific trial each participant was
undergoing. To ensure that the investigators would not be able
to differentiate between trials, participants were given a shirt
and athletic pants to wear upon exiting the chamber after all
trials. These clothes had been previously exposed to SHS inside
the chamber and emitted a strong tobacco scent.
The present is a new experiment, yet methods regarding the
SHS exposure as well as measurements for serum and urine
cotinine and cytokine production have been used previously in
our laboratory and are described in detail elsewhere (11, 12).
Further detail on the method for making these measurements is
provided in the online supplement.
Lung Function
FVC, FEV1, FEV1/FVC ratio, peak expiratory flow (PEF), as
well as maximum expiratory flow (MEF) when 75%, 50% and
25% of FVC remains in the lungs (MEF75%, MEF50%, and
MEF25%, respectively) were measured using a hand-held spi-
rometer (Spiromed 180, Fukuda Sangyo, Pulmonary Products,
Tokyo, Japan) calibrated before each use. The lung function
assessment protocol conformed to the American Thoracic
Society recommendations (21).
Statistical Analysis
Given the significant sexual dimorphism in the acute SHS effects
(12), participants’ data were divided by sex into groups. A two-
group (men, women) by four-times (TB, T0, T1 and T3) factorial
analysis of variance (ANOVA), followed by sex-specific post-hoc
t tests incorporating a Bonferroni adjustment, was used to assess
the effect of sex and time after SHS on all the examined variables.
Given the statistically significant effect of SHS on FEV1 and the
FEV1/FVC ratio (see RESULTS), sex-specific stepwise multiple
linear regression analyses incorporating backward elimination at
the P, 0.05 level were introduced to model the effect of cotinine
and cytokine concentrations (independent variables) on these
lung function parameters (dependent variables). The level of
significance was set at P , 0.05 except for post-hoc tests in which
a Bonferroni adjustment was applied. Additional detail on the
statistical analyses is provided in the online supplement.
Figure 1. Overview of the experimental design: In the
baseline trial (TB) participants’ data were collected at
1200 hours without any secondhand smoke (SHS) expo-
sure. In the remaining trials, participants were exposed to
SHS for 1 hour either at 0800 hours (T3), 1000 hours (T1)
or at 1100 hours (T0), while data were collected at 1200
hours. SHS 5 secondhand smoke.
Figure 2. Mean 6 SD of FEV1 for men (triangles) and women (squares)
in each trial. Values dropped 9.7% in men and 13.2% in women
between TB and T0. a 5 significant (P , 0.05) difference from previous
trial (timepoint).
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RESULTS
The factorial ANOVA (R2 5 0.799; adjR25 0.774) revealed that
the values of all variables except FVC (P 5 0.999), PEF (P 5
0.889), and IL-4 (P 5 0.079) changed depending on the time of
measurement (significant main effect: F(36, 141) 5 6.687; P ,
0.001). The same analysis also showed that the values of all
variables except IL-4 (P 5 0.218) were different between sexes
(significant main effect: F(12, 45) 5 35.488, P , 0.001). Further-
more, the aforementioned time-induced changes in cotinine,
lung function, and cytokines were not the same for men and
women (significant interaction effect: F(36, 141) 5 2.127; P5 0.001).
For instance, IL-4 and tumor necrosis factor (TNF)-a increased
after the SHS exposure only in men (P , 0.05), whereas in
women there was no change across time (P . 0.05).
As expected, the sex-specific post-hoc t tests (Figure 2 and
Tables 1 and 2) demonstrated an effect of SHS on pulmonary
function characterized by an acute response at T0 that was
attenuated with longer exposure lags (T1 and T3). Specifically,
although at T0 the values of FEV1, FEV1/FVC ratio, MEF75%,
MEF50% and MEF25% were markedly reduced (P , 0.05), at T3
they were at levels similar to TB (P . 0.05). In contrast, mean
values at T3 of cotinine levels and all inflammatory markers
except TNF-a remained higher than TB levels (P , 0.05).
Notably, in some cases (e.g., IL-4, IL-6, and IFN-g) the effect of
SHS increased with greater lag.
The stepwise multiple linear regression analyses for FEV1
demonstrated an inverse association with IL-5 (b 5 20.007; P 5
0.05) in men (R25 0.339; F(1, 30)5 3.886;P5 0.05) as well as inverse
associations with IL-6 (b 5 20.16; P , 0.001) and serum cotinine
(b520.025;P, 0.001) in women (R25 0.645; F(3, 28)5 6.661;P5
0.002). The same analysis for FEV1/FVC ratio revealed an inverse
association with IL-5 (b 5 20.002; P5 0.022) in men (R2 5 0.41;
F (2, 29)5 2.931;P5 0.05) as well as inverse associations with IL-5
(b 5 20.003; P 5 0.01) and IFN-g (b 5 20.144; P 5 0.034) in
women (R2 5 0.47, F(2, 29) 5 4.102; P 5 0.027).
DISCUSSION
To the best of our knowledge, this is the first experiment to
investigate the duration of the acute SHS effects on lung
function and cytokine levels. Our results demonstrated that 1
hour of moderate SHS exposure generates significant decre-
ments on lung function and marked increases in the vast
majority of the cytokines investigated. More important, whereas
most SHS-induced effects on lung function appear to recede
within 60 minutes, inflammatory cytokines remain elevated for
at least 3 hours after exposure.
Previous epidemiological studies have shown that chronic
SHS is associated with a reduction of several lung function
measures, yet these findings have not been consistent, and
methodological issues have constrained interpretation of the
findings (22). The present data show clearly a significant effect
of acute SHS on FEV1, FEV1/FVC ratio, MEF75%, MEF50%,
and MEF25%. The SHS-induced changes in FEV1 and FEV1/
FVC ratio resemble closely the airway obstruction apparent in
smokers (23), although the present FEV1/FVC ratio at T0 was
0.74 and not 0.70. This notion is further supported by the SHS-
induced changes in MEF75%, MEF50%, and MEF25%, which
show a MEF-volume curve convex to the volume axis with an
increasing curve in late expiration. These results are typical for
obstructive diseases like cystic fibrosis, bronchial asthma, and
wheezy bronchitis (24). Furthermore, our findings confirm
a previous epidemiological study suggesting that acute SHS
was associated with symptoms of chronic bronchitis (25).
The mechanism underlying the airflow limitation observed
immediately after the SHS exposure (i.e., T0) may be related to
SHS-induced airway irritation. Previous research has shown that
cigarette smoke inhalation elicits irregular breathing patterns,
cough reflex, and bronchoconstriction through activation of vagal
afferents (26). On the other hand, recent evidence suggests that
SHS induces rapid profibrotic growth factor production in the
walls of small airways through an oxidant mechanism (9). These
findings suggest that the initial response to cigarette smoke may
reflect direct induction of growth factors resulting in airway
remodeling. Fibrosis and thickening of the airway wall, particu-
larly in the subepithelial compartment in the small airways, are
an important part of the pathogenesis of SHS-induced airflow
limitation, yet the precise effect of airway remodeling type on
airflow obstruction remains to be determined (9).
TABLE 1. LUNG FUNCTION AND TIME COMPARISONS FOR MEN
AND WOMEN IN EACH TRIAL
TB T0 T1 T3
FVC, L M 6.0 6 0.7 6.0 6 0.7 6.0 6 0.8 5.9 6 0.6
W 4.0 6 0.6 4.0 6 0.6 4.0 6 0.5 4.1 6 0.5
FEV1, L M 4.9 6 0.4 4.5 6 0.3* 4.7 6 0.3 4.9 6 0.3
W 3.7 6 0.4 3.2 6 0.3* 3.6 6 0.4 3.7 6 0.3
FEV1/FVC M 0.8 6 0.1 0.7 6 0.1* 0.8 6 0.1 0.8 6 0.1
W 0.9 6 0.1 0.8 6 0.1* 0.9 6 0.1* 0.9 6 0.1
PEF, Lsec21 M 9.8 6 0.7 9.5 6 0.3 9.6 6 1.0 9.7 6 0.9
W 7.8 6 1.2 7.8 6 1.2 8.1 6 0.9 8.1 6 0.9
MEF75%, Lsec21 M 8.0 6 0.3 6.9 6 0.4* 6.9 6 0.6† 7.3 6 0.7
W 6.6 6 0.4 6.0 6 0.3* 6.3 6 0.3 6.4 6 0.4
MEF50%, Lsec21 M 5.8 6 0.5 4.7 6 0.5* 4.7 6 0.8† 5.2 6 0.9
W 4.7 6 0.3 4.1 6 0.1* 4.4 6 0.3 4.6 6 0.3
MEF25%, Lsec21 M 2.8 6 0.3 2.4 6 0.3* 2.5 6 0.3 2.6 6 0.3
W 3.1 6 0.5 2.7 6 0.2 2.7 6 0.3 3.0 6 0.3
Definition of abbreviations: M 5 men; MEF75%, MEF50%, MEF25%: maximum
expiratory flow when 75%, 50% and 25% of FVC remains in the lungs,
respectively; PEF 5 peak expiratory flow; TB 5 time at baseline; T0, T1, T3 5
time at 0, 1, and 3 hours, respectively; W 5 women.
Values are mean 6 SD. All sex-comparisons were significant at P , 0.05 except
MEF50% at T1 and T3 and MEF25% at TB and T1.
* Significant difference from previous trial (time-point); P , 0.05.
† Significant difference of T1 and T3 from TB; P , 0.05.
TABLE 2. COTININE CONCENTRATIONS, CYTOKINE
LEVELS, AND TIME COMPARISONS FOR MEN AND
WOMEN IN EACH TRIAL
TB T0 T1 T3
Serum cotinine,
ngmL21
M 8.5 6 2.5 27.4 6 12.1* 39.9 6 14.1† 38.0 6 10.1†
W 9.3 6 3.6 21.8 6 8.3* 35.6 6 9.7*† 32.9 6 10.3†
Urine cotinine,
ngml21
M 6.4 6 2.2 21.1 6 10.6 29.6 6 13.0† 29.4 6 13.8†
W 7.9 6 3.3 22.0 6 8.3* 30.5 6 8.8† 28.3 6 10.5†
IL-4, pgml21 M 44.9 6 3.5‡ 49.6 6 4.3* 46.4 6 4.5 47.0 6 4.6†‡
W 37.7 6 6.4‡ 43.8 6 5.3 43.3 6 6.1 41.4 6 4.3‡
IL-5, pgml21 M 37.2 6 6.8 69.7 6 7.5*‡ 79.7 6 5.2*†‡ 65.7 6 5.8*†‡
W 35.1 6 1.4 56.0 6 8.0*‡ 66.4 6 2.6*†‡ 54.5 6 7.6*†‡
IL-6, pgml21 M 2.4 6 0.3 6.4 6 2.5* 8.2 6 1.3† 9.0 6 1.5†‡
W 2.5 6 0.4 5.8 6 1.9* 7.4 6 1.2† 6.3 6 1.1†‡
TNF-a, pgml21 M 9.3 6 1.6‡ 12.4 6 2.4*‡ 11.2 6 2.1‡ 8.4 6 0.9*‡
W 6.4 6 1.5‡ 8.0 6 2.2d 7.4 6 1.8‡ 6.4 6 1.2‡
IFN-g, IUml21 M 0.3 6 0.2 0.6 6 0.2*‡ 0.8 6 0.2†‡ 0.7 6 0.1†‡
W 0.3 6 0.1 0.4 6 0.1‡ 0.6 6 0.2†‡ 0.5 6 0.2†‡
Definition of abbreviations: M5men; TB5 time at baseline; T0, T1, T35 time at
0, 1, and 3 hours, respectively; TNF-a: tumor necrosis factor-a; W 5 women.
Values are mean 6 SD.
* Significant difference from previous trial (time-point); P , 0.05.
† Significant difference of T1 and T3 from TB; P , 0.05.
‡ Significant difference between sexes for the same measurement; P , 0.05.
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The observed SHS-induced increase in circulating inflamma-
tory markers extends the findings of a small number of previous
human experiments reporting SHS-induced increases of IL-1b
(12), white blood cell count, C-reactive protein, homocysteine,
fibrinogen (17), as well as leukocyte counts accompanied by an
activation of the immune cells (27). The present results also
confirm another study by our group reporting an increased
SHS-induced inflammatory reaction in men compared with
women (12). In the present experiment we found that IL-4
and TNF-a increased only in men, while there was significant
sexual difference in IL-5, IL-6 and IFN-g after SHS exposure.
Given that the cytokines investigated are closely associated
with the chronic lung inflammation and structural changes
observed in pulmonary disease patients (28), it could be
suggested that chronic SHS may have clinical implications—
especially in men, given their increased inflammatory
response—such as increased susceptibility to infection, chronic
lung inflammation, as well as pathological airway changes
including chronic obstructive pulmonary diseases. The present
concentrations of IL-5, IL-6, and IFN-g after SHS exposure
were linked with the marked decreases in FEV1 and FEV1/FVC
ratio, confirming the association between circulating inflamma-
tion markers and FEV1 (29). In turn, lower FEV1 and FEV1/
FVC ratio are associated with a greater prospective risk of
cardiovascular mortality among nonsmokers (22). The current
finding that inflammatory cytokine levels remain elevated for at
least 3 hours after SHS exposure alludes to chronic low-grade
systemic inflammation in individuals exposed to SHS on a daily
basis and/or at higher smoke concentrations. This is particularly
true for IFN-g, which is closely linked with chronic obstructive
pulmonary disease and asthma (30). At present, the physiolog-
ical mechanisms linking low-grade systemic inflammation and
pulmonary disease is not entirely understood (31). However,
a number of studies have reported higher levels of systemic
fibrinogen and C-reactive protein in individuals with impaired
lung function (32) and in patients suffering from chronic
obstructive pulmonary disease (33).
Prosmoking groups use the reduced sales of tobacco products
in selected few countries to argue that smoking bans are not
necessary. This delusion is accompanied by an equally pernicious
myth that there is ‘‘no scientific basis for claims that brief, acute,
transient exposure to secondhand smoke. . .represents any other
significant acute. . .health hazard in nonsmokers’’ (6). Several
studies referenced in the present article reject this argument. In
fact, to our knowledge, all human exposure studies investigating
the acute effects of SHS have reported significant detrimental
results. With regard to the present experiment, it is important to
note that the observed changes in lung function and inflamma-
tory cytokines did not arise from an extreme and/or prolonged
SHS exposure. The reported cotinine levels suggest a moderate
and brief SHS exposure (34) confirming a successful simulation
of a bar/restaurant smoking environment. Further, it is not
possible that the comparatively long half-life of cotinine, the
diurnal variation in lung function and inflammatory markers, or
the investigators’ expectations were reflected in our results. This
is because the adopted design enabled data collection without
SHS exposure (TB) as well as immediately after (T0), 1 hour after
(T1), and 3 hours after SHS exposure (T3), with the data being
collected at the same time of the day and without the effect of
previous or subsequent measurements insofar as only one
assessment was conducted per trial. Yet, our lung function results
are limited by the impossibility of blinding our participants to
SHS exposure. However, suggestibility does not appear to
underlie acute physiological responses to SHS (35). Moreover,
the present SHS-induced inflammatory reaction observed at T0
was similar to a previous study by our group that incorporated
a repeated measures–randomized block design with a sham SHS
exposure (11), thus supporting our protocol. With these in mind,
it is concluded that a 1-hour SHS exposure at levels similar to
those of bars and restaurants is accompanied by significant
decreases in lung function and marked increases in inflammatory
cytokines, particularly in men. Importantly, although most SHS-
induced effects on lung function appear to recede within
60 minutes, inflammatory cytokines remain elevated for at least
3 hours after SHS exposure.
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